Neonc Technologies Holdings, Inc. (NTHI)
Neonc Technologies Holdings, Inc. is a biotechnology firm specializing in targeted drug delivery for central nervous system diseases. Their primary focus is on developing therapies like NEO100 and NEO212 to combat conditions such as glioblastoma.
Company Overview
Neonc Technologies Holdings pioneers targeted drug delivery for central nervous system disorders, leveraging innovative molecular technology to enhance therapeutic efficacy, with lead candidates NEO100 and NEO212 poised to disrupt the treatment landscape for diseases like glioblastoma and offering significant growth potential.
Investment Thesis
Investing in Neonc Technologies Holdings, Inc. (NTHI) presents a compelling opportunity due to its innovative approach to treating central nervous system diseases. The company's focus on targeted drug delivery, exemplified by its lead candidates NEO100 and NEO212, addresses a critical need for more effective and less toxic therapies. The ongoing Phase 2a clinical trials for NEO100 in glioblastoma represent a significant near-term catalyst. Positive trial results could lead to accelerated regulatory pathways and eventual commercialization. Furthermore, the completion of preclinical testing for NEO212 positions it for potential clinical development and future revenue streams. With a market cap of $0.19 billion and a high beta of 3.30, NTHI offers high-growth potential, albeit with substantial risk, making it suitable for investors with a high-risk tolerance seeking exposure to cutting-edge biotechnology.
Key Highlights
- Market capitalization of $0.19 billion reflects the company's current valuation and potential for growth.
- Gross margin of 100.0% indicates efficient cost management in research and development activities.
- Phase 2a clinical trials for NEO100 represent a critical milestone in the development of a targeted glioblastoma therapy.
- Completion of preclinical testing for NEO212 positions it for future clinical development and potential revenue generation.
- Negative P/E ratio of -3.59 reflects the company's current lack of profitability due to ongoing research and development expenses.
Competitors
Strengths
- Innovative targeted drug delivery technology.
- Lead drug candidate (NEO100) in Phase 2a clinical trials.
- Experienced management team with expertise in biotechnology.
- Strong intellectual property protection.
Weaknesses
- Limited financial resources.
- Small team size.
- Dependence on the success of a few key drug candidates.
- Lack of commercialization experience.
Catalysts
- Upcoming: Announcement of Phase 2a clinical trial results for NEO100.
- Upcoming: Initiation of clinical trials for NEO212.
- Ongoing: Progress in developing new drug candidates for CNS diseases.
- Ongoing: Potential strategic partnerships or collaborations.
- Ongoing: Advancements in targeted drug delivery technology.
Risks
- Potential: Clinical trial failures for NEO100 or NEO212.
- Potential: Regulatory delays or rejection of drug candidates.
- Ongoing: Competition from larger pharmaceutical companies with greater resources.
- Ongoing: Difficulty in raising sufficient capital to fund research and development.
- Potential: Intellectual property infringement or challenges to patent protection.
Growth Opportunities
- Advancement of NEO100 through Clinical Trials: The successful completion of Phase 2a clinical trials for NEO100 and subsequent progression through further clinical stages represents a significant growth opportunity. Positive clinical data could lead to accelerated regulatory approval and eventual commercialization, capturing a share of the glioblastoma treatment market, which is projected to reach billions of dollars annually. The timeline for this growth opportunity is dependent on clinical trial outcomes and regulatory timelines.
- Development and Commercialization of NEO212: Following the completion of preclinical testing, NEO212 holds potential for further development and commercialization. This covalently conjugated molecule, combining temozolomide with perillyl alcohol, could offer improved therapeutic outcomes for various cancers. Successful clinical trials and regulatory approval could lead to a new revenue stream for Neonc Technologies, expanding its market presence and driving growth. The timeline for this opportunity depends on securing funding for clinical trials.
- Expansion of Targeted Delivery Technology Platform: Neonc Technologies can leverage its expertise in targeted drug delivery to develop new therapies for other CNS diseases beyond glioblastoma. By expanding its pipeline with additional drug candidates targeting different neurological disorders, the company can diversify its revenue streams and reduce its reliance on a single product. The market for CNS disease treatments is vast, offering significant growth potential.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions can provide Neonc Technologies with access to additional funding, expertise, and resources. Collaborations can accelerate the development and commercialization of its drug candidates, increasing its chances of success in the competitive biotechnology industry. These partnerships can also validate the company's technology and attract further investment.
- Out-Licensing or Acquisition of Technology: Neonc Technologies could explore opportunities to out-license its targeted drug delivery technology to other companies or be acquired by a larger pharmaceutical firm. This would provide a significant return on investment for early investors and validate the value of its technology platform. The biotechnology industry is characterized by frequent mergers and acquisitions, making this a viable exit strategy for Neonc Technologies.
Opportunities
- Positive clinical trial results for NEO100.
- Expansion of the drug pipeline with new CNS disease targets.
- Strategic partnerships with larger pharmaceutical companies.
- Out-licensing or acquisition of the company's technology.
Threats
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from larger pharmaceutical companies.
- Difficulty in raising capital.
Competitive Advantages
- Proprietary molecular technology for targeted drug delivery.
- Patent protection for its lead drug candidates and delivery methods.
- Clinical trial data demonstrating the efficacy and safety of its therapies.
- Expertise in central nervous system disease treatment.
- First-mover advantage in developing targeted therapies for specific CNS conditions.
About
Neonc Technologies Holdings, Inc., founded in 2023, is a biotechnology company dedicated to revolutionizing the treatment of central nervous system (CNS) diseases through advanced molecular technology. The company focuses on developing novel methods for targeted drug delivery, aiming to improve the efficacy and reduce the side effects of existing therapies. Their lead product, NEO100, is currently in Phase 2a clinical trials for the treatment of glioblastoma, an aggressive form of brain cancer. NEO100 represents a significant advancement in targeted cancer therapy, designed to deliver therapeutic agents directly to tumor cells while minimizing exposure to healthy tissue. Another key asset in their pipeline is NEO212, a covalently conjugated molecule that combines the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 has completed preclinical testing and shows promise for enhanced therapeutic outcomes. Based in Los Angeles, California, Neonc Technologies is committed to addressing the unmet needs in CNS disease treatment through innovative research and development. The company's strategic focus on targeted delivery technologies positions it as a potential leader in the biotechnology sector, offering hope for more effective and less toxic treatments for patients with debilitating CNS conditions. The company's small size, with only 8 employees, allows for agility and focused execution on its core programs.
What They Do
- Develops novel molecular technology for targeted drug delivery.
- Focuses on treating central nervous system (CNS) diseases.
- Conducts clinical trials for its lead drug candidates.
- Seeks to improve the efficacy and reduce side effects of existing therapies.
- Researches and develops new treatments for glioblastoma and other cancers.
- Combines chemotherapeutic drugs with innovative delivery methods.
Business Model
- Develops and patents novel molecular technology.
- Conducts preclinical and clinical trials to validate drug efficacy and safety.
- Seeks regulatory approval for its drug candidates.
- Potentially commercializes its drugs directly or through partnerships.
- Generates revenue through drug sales, licensing agreements, or acquisition.
Industry Context
Neonc Technologies Holdings operates within the competitive biotechnology industry, which is characterized by rapid innovation and high regulatory hurdles. The market for CNS disease treatments is substantial and growing, driven by an aging population and increasing prevalence of neurological disorders. The company's focus on targeted drug delivery aligns with the industry trend toward personalized medicine and more effective therapies. Competitors include companies developing similar targeted therapies or alternative treatments for CNS diseases. Success in this industry requires strong research and development capabilities, strategic partnerships, and successful navigation of the regulatory approval process.
Key Customers
- Patients suffering from central nervous system diseases, particularly glioblastoma.
- Healthcare providers who prescribe and administer the company's therapies.
- Hospitals and cancer centers that utilize the company's products.
- Pharmaceutical companies interested in licensing or acquiring the company's technology.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $39,990 | -$38M | $-2.10 |
Source: Company filings
Chart & Info
Price Chart
Neonc Technologies Holdings, Inc. (NTHI) stock price: $9.15 (+0.27, +3.04%)
Why Bull
- •Neonc's recent insider buying suggests those in the know see long-term value, a potential confidence signal.
- •Positive chatter in the trading community indicates growing interest and belief in Neonc's future prospects.
- •Market perception seems to be shifting, with more analysts highlighting Neonc's potential in emerging tech. Think early days of Palantir.
- •There's a growing narrative around Neonc becoming a key player in its sector, fueling speculative buying and long positions.
Why Bear
- •Recent bearish sentiment in some corners of the community points to concerns about Neonc's execution capabilities.
- •Despite overall positivity, some analysts are drawing parallels to past hyped tech companies that failed to deliver. Remember Pets.com?
- •Insider activity, while mostly positive, has seen some minor selling, potentially signaling short-term profit-taking.
- •Increased market volatility could disproportionately affect growth stocks like Neonc, leading to a potential sell-off. Similar to what happened to many high-growth stocks in early 2022.
Latest News
-
New to The Street to Broadcast Show #726 on Bloomberg at 6:30 PM EST Featuring Vivos Therapeutics (NASDAQ:VVOS), Aeries Technology (NASDAQ:AERT), Virtuix Holdings (NASDAQ:VTIX), and Stardust Power (NASDAQ:SDST)
ACCESS Newswire · Feb 14, 2026
-
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga · Feb 11, 2026
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Feb 10, 2026
Technical Analysis
Rationale
AI-generated technical analysis for NTHI including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Neonc Technologies Holdings, Inc. (NTHI) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for NTHI.
Make a Prediction
Set your price target for Neonc Technologies Holdings, Inc. (NTHI), choose a timeframe, and track your prediction accuracy.
Current price: $9.15
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NTHI.
Price Targets
Wall Street price target analysis for NTHI.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 5/100
Revenue growth data is currently unavailable for this company.
-
Gross Margin 10/100
Gross margin of 100.0% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates NTHI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
New to The Street to Broadcast Show #726 on Bloomberg at 6:30 PM EST Featuring Vivos Therapeutics (NASDAQ:VVOS), Aeries Technology (NASDAQ:AERT), Virtuix Holdings (NASDAQ:VTIX), and Stardust Power (NASDAQ:SDST)
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
Frequently Asked Questions
What does Neonc Technologies Holdings, Inc. do?
Neonc Technologies Holdings, Inc. is a biotechnology company focused on developing and commercializing novel molecular technologies for targeted drug delivery, primarily for the treatment of central nervous system (CNS) diseases. Their lead product, NEO100, is currently in Phase 2a clinical trials for glioblastoma, an aggressive brain cancer. The company aims to improve the efficacy and reduce the side effects of existing therapies by delivering drugs directly to the affected tissues. Additionally, they are developing NEO212, a molecule combining temozolomide with perillyl alcohol, which has completed preclinical testing and shows promise for enhanced therapeutic outcomes.
Is NTHI stock a good buy?
Evaluating NTHI stock requires careful consideration of its high-risk, high-reward profile. The company's innovative approach to targeted drug delivery and its lead candidate, NEO100, hold significant potential. However, the biotechnology industry is inherently risky, with clinical trial failures and regulatory hurdles being common challenges. The negative P/E ratio of -3.59 reflects the company's current lack of profitability. Investors should assess their risk tolerance and conduct thorough due diligence before investing in NTHI, considering both the potential upside and the inherent risks associated with early-stage biotechnology companies. The high beta of 3.30 indicates high volatility.
What are the main risks for NTHI?
The main risks for Neonc Technologies Holdings, Inc. include the potential failure of clinical trials for its lead drug candidates, particularly NEO100 and NEO212. Clinical trial failures can result in significant financial losses and delays in product development. Regulatory hurdles and delays in obtaining FDA approval also pose a significant risk. Furthermore, the company faces competition from larger pharmaceutical companies with greater resources and established market presence. Raising sufficient capital to fund ongoing research and development activities is another key risk, as the company's financial resources are limited. Protecting its intellectual property and avoiding infringement claims are also critical challenges.
Is NTHI a good stock to buy?
Whether NTHI is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the NTHI MoonshotScore?
The MoonshotScore for NTHI is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is NTHI data updated?
NTHI stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to NTHI is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for NTHI?
Growth catalysts for Neonc Technologies Holdings, Inc. (NTHI) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Neonc Technologies Holdings, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are NTHI's main competitors?
Neonc Technologies Holdings, Inc. (NTHI) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether NTHI has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about NTHI?
Wall Street analyst coverage for NTHI includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is NTHI's market cap?
Market capitalization (market cap) for NTHI is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows NTHI's current market cap alongside enterprise value and other valuation metrics.
How has NTHI stock performed recently?
NTHI's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing NTHI's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in NTHI?
Key risk categories for NTHI include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures NTHI's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling NTHI?
Insider trading activity for NTHI tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is NTHI a good stock for beginners?
Neonc Technologies Holdings, Inc. (NTHI) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is NTHI for first-time investors?
Every stock carries risk, including Neonc Technologies Holdings, Inc. (NTHI). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like NTHI.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on limited publicly available data.
- Clinical trial outcomes are inherently uncertain.
- Investment in biotechnology companies carries significant risk.